Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640753 | 1.00 | L3MBTL1 (0.42) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL16640749 | 1.00 | L3MBTL1 (0.42) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL13384038 | 0.89 | L3MBTL1 (0.45) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL15820474 | 0.82 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL15820472 | 0.82 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL16640754 | 0.81 | FUCA1 (0.38) | — | |
| SCHEMBL18251216 | 0.80 | L3MBTL1 (0.47) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL23848882 | 0.79 | GBA1 (0.46) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14028866 | 0.79 | GBA1 (0.46) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL8347365 | 0.79 | GBA1 (0.46) | LGALS1LGALS3LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632135-B2 | Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10632135-B2 | Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease | ICAM1, VCAM1, EPCAM | L3MBTL1 4499/4885MAPT 1300/4885LGALS1 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.